Radiopharm Theranostics IPO
McCullough Robertson successfully advised on the $50 Million IPO of Radiopharm Theranostics (ASX:RAD).
This follows its $20 Million Pre-IPO capital raising in August of 2021 which McCullough Robertson also advised on.
Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic uses. This IPO will provide Radiopharm Theranostics with the opportunity to continue developing the five phase two clinical trials, and two phase one trials that are currently underway.